Anticancer mechanisms and clinical application of alkylphospholipids

Article ID	Journal	Published Year	Pages	File Type
8302873	Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids	2013	12 Pages	PDF

Abstract

âº Alkylphospholipids (ALPs) inhibit PI3K-Akt, Raf-Erk1/2 pathways and PC biosynthesis. âº Cells internalize ALPs via CDC50a flippase and via raft-mediated endocytosis. âº ALPs activate stress pathways and induce apoptosis in proliferating cells. âº ALP (perifosine) sensitizes rapamycin- and traditional chemo- and radiotherapy. âº Akt inhibitor perifosine overcomes tumor cell resistance to other anticancer agents.

Keywords

PIP2 PLC Erucylphosphocholine DISC TNF ERK c-FLIPL FADD mTOR ASK1 Phosphatidylinositol-4,5 bisphosphate PIP3 Jnk PKD SAPK EGF PI3K c-Jun N-terminal kinase CTP:phosphocholine cytidylyltransferase MAPK ROS ALP Alkylphospholipid Akt sphingomyelin synthase Pleckstrin homology domain Anticancer therapy endoplasmic reticulum epidermal growth factor tumor necrosis factor phosphatidylinositol phosphatidylcholine Phosphatidylinositol 3-kinase phospholipase C TRAIL TNF-related apoptosis-inducing ligand Multiple myeloma mammalian target of rapamycin Fas-associated protein with death domain protein kinase D mitogen-activated protein kinase Stress-activated protein kinase Perifosine SMS death-inducing signaling complex SHIP-1 extracellular-signal-regulated kinase apoptosis signal-regulating kinase 1 Reactive oxygen species